The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Contraceptive Devices, Female

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Contraceptive Devices, Female

 

High impact information on Contraceptive Devices, Female

 

Biological context of Contraceptive Devices, Female

 

Anatomical context of Contraceptive Devices, Female

 

Associations of Contraceptive Devices, Female with chemical compounds

  • The ability of polysiloxane vaginal rings containing 17 beta-Estradiol (E2) to deliver E2 into the systemic circulation at a steady rate over long periods of time was evaluated in castrate and postmenopausal volunteers [19].
  • Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials [9].
  • RESULTS: Continuous, zero-order release of TMC120 from core-type vaginal rings was observed in vitro over a 71 day period, equivalent to 136 microg/day [2].
  • METHODS: Women were randomly assigned to either contraceptive vaginal ring or a 20 microg ethinyl estradiol oral contraceptive pill use for 3 consecutive 28-day cycles, directly followed by 3 cycles of the study drug not initially assigned [20].
  • Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring [21].
 

Gene context of Contraceptive Devices, Female

 

Analytical, diagnostic and therapeutic context of Contraceptive Devices, Female

References

  1. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Pinkerton, J.V., Shifren, J.L., La Valleur, J., Rosen, A., Roesinger, M., Siddhanti, S. Menopause (New York, N.Y.) (2003) [Pubmed]
  2. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. Malcolm, R.K., Woolfson, A.D., Toner, C.F., Morrow, R.J., McCullagh, S.D. J. Antimicrob. Chemother. (2005) [Pubmed]
  3. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Koetsawang, S., Ji, G., Krishna, U., Cuadros, A., Dhall, G.I., Wyss, R., Rodriquez la Puenta, J., Andrade, A.T., Khan, T., Kononova, E.S. Contraception. (1990) [Pubmed]
  4. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology. Schwan, A., Ahrén, T., Victor, A. Contraception. (1983) [Pubmed]
  5. A prospective study of risk factors for symptomatic urinary tract infection in young women. Hooton, T.M., Scholes, D., Hughes, J.P., Winter, C., Roberts, P.L., Stapleton, A.E., Stergachis, A., Stamm, W.E. N. Engl. J. Med. (1996) [Pubmed]
  6. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. Meyskens, F.L., Surwit, E., Moon, T.E., Childers, J.M., Davis, J.R., Dorr, R.T., Johnson, C.S., Alberts, D.S. J. Natl. Cancer Inst. (1994) [Pubmed]
  7. A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. Meyskens, F.L., Graham, V., Chvapil, M., Dorr, R.T., Alberts, D.S., Surwit, E.A. J. Natl. Cancer Inst. (1983) [Pubmed]
  8. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. Elkik, F., Basdevant, A., Jackanicz, T.M., Guy-Grand, B., Mercier-Bodard, C., Conard, J., Bardin, C.W., Corvol, P. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  9. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Dogterom, P., van den Heuvel, M.W., Thomsen, T. Clinical pharmacokinetics. (2005) [Pubmed]
  10. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Timmer, C.J., Mulders, T.M. Clinical pharmacokinetics. (2000) [Pubmed]
  11. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. Al-Azzawi, F., Lees, B., Thompson, J., Stevenson, J.C. Menopause (New York, N.Y.) (2005) [Pubmed]
  12. Genital stimulation facilitates maternal behavior in estrous ewes. Poindron, P., Rempel, N., Troyer, A., Krehbiel, D. Hormones and behavior. (1989) [Pubmed]
  13. Contraception with progestogens and progesterone during lactation. Shaaban, M.M. J. Steroid Biochem. Mol. Biol. (1991) [Pubmed]
  14. Nestorone: clinical applications for contraception and HRT. Sitruk-Ware, R., Small, M., Kumar, N., Tsong, Y.Y., Sundaram, K., Jackanicz, T. Steroids (2003) [Pubmed]
  15. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Zegers-Hochschild, F., Balmaceda, J.P., Fabres, C., Alam, V., Mackenna, A., Fernández, E., Pacheco, I.M., Sepúlveda, M.S., Chen, S., Borrero, C., Borges, E. Hum. Reprod. (2000) [Pubmed]
  16. Pharmacokinetics of estrogen. Stumpf, P.G. Obstetrics and gynecology. (1990) [Pubmed]
  17. Effect of a resorbable bone graft material on orthodontic tooth movement through surgical defects in the cat mandible. Sheats, R.D., Strauss, R.A., Rubenstein, L.K. J. Oral Maxillofac. Surg. (1991) [Pubmed]
  18. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Lose, G., Englev, E. BJOG : an international journal of obstetrics and gynaecology. (2000) [Pubmed]
  19. Development of a vaginal ring for achieving physiologic levels of 17 beta-estradiol in hypoestrogenic women. Stumpf, P.G., Maruca, J., Santen, R.J., Demers, L.M. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  20. A comparison between the vaginal ring and oral contraceptives. Veres, S., Miller, L., Burington, B. Obstetrics and gynecology. (2004) [Pubmed]
  21. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Gao, J., Sun, H.Z., Song, G.Y., Ma, L.Y. Fertil. Steril. (1986) [Pubmed]
  22. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women. Cekan, S.Z., Jia, M., Landgren, B.M., Diczfalusy, E. Contraception. (1985) [Pubmed]
  23. LARS treatment for mandibular growth followed by open coiled springs for space gaining. Williamson, E.H. Facial orthopedics and temporomandibular arthrology. (1987) [Pubmed]
  24. Luteinizing hormone-releasing hormone, ovariectomy, and silastic vaginal rings in the Rhesus monkey. Kragt, C.L., Gala, R.R. Fertil. Steril. (1977) [Pubmed]
  25. Randomized comparison of a new estradiol-releasing vaginal ring versus estriol vaginal pessaries. Saure, A. Am. J. Obstet. Gynecol. (1995) [Pubmed]
  26. Estradiol-delivering vaginal rings for hormone replacement therapy. Nash, H.A., Alvarez-Sanchez, F., Mishell, D.R., Fraser, I.S., Maruo, T., Harmon, T.M. Am. J. Obstet. Gynecol. (1999) [Pubmed]
  27. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Henriksson, L., Stjernquist, M., Boquist, L., Alander, U., Selinus, I. Am. J. Obstet. Gynecol. (1994) [Pubmed]
  28. Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices. Díaz, S., Zepeda, A., Maturana, X., Reyes, M.V., Miranda, P., Casado, M.E., Peralta, O., Croxatto, H.B. Contraception. (1997) [Pubmed]
  29. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids. de Leede, L.G., Govers, C.P., de Nijs, H. Contraception. (1986) [Pubmed]
 
WikiGenes - Universities